Vault Nanoparticles Containing an Adenovirus-Derived Membrane Lytic Protein Facilitate Toxin and Gene Transfer
Source abstract
Abstract
Nonviral methods of gene delivery possess several advantages over that of viral-based vectors, including having increased safety. However, the ability to achieve effective transport of therapeutic molecules across host cell membranes via nonviral methods remains a significant goal. Cell-derived nanoparticles known as vaults have been proposed as novel candidate transfer vehicles for various foreign molecules. Recombinant vault particles enter cells via macropinocytosis or phagocytosis but lack demonstrable membrane penetrating activity. To explore the feasibility of improving vault penetration into target cells, we incorporated the membrane lytic domain of adenovirus protein VI (pVI) into the interior of recombinant vault particles via fusion to the vault poly(ADP-ribose) polymerase (VPARP) interaction domain. The membrane lytic activity of the pVI domain was retained upon incorporation into vault particles. Moreover, internalization of vault-pVI complexes into murine macrophages promoted co-delivery of a soluble ribotoxin or a cDNA plasmid encoding GFP. These findings indicate that vault particles can be modified to enhance cell transfer of selected biomolecules.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Virus-based gene therapy research · CRISPR and Genetic Engineering · CAR-T cell therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California 92037
DuPont Central R&D, Experimental Station, E328/203 L, Wilmington, Delaware 19880-0328
Department of Microbiology & Immunology, Loyola University Chicago, Maywood, Illinois 60153
Department of Biological Chemistry, David Geffen School of Medicine and California NANOSystems Institute, University of California, Los Angeles, California 90095
References (36)
Show source-provided references
1. Park T. G. · Adv. Drug Delivery Rev. · 2006 · 58 · 46710.1016/j.addr.2006.03.007 ↗
2. Wiethoff C. M. · J. Pharm. Sci. · 2004 · 93 · 10810.1002/jps.10519 ↗
3. Levine B. L. · Proc. Natl. Acad. Sci. U.S.A. · 2006 · 103 · 1737210.1073/pnas.0608138103 ↗
4. Tatsis N. · Mol. Ther. · 2004 · 10 · 61610.1016/j.ymthe.2004.07.013 ↗
5. Kickhoefer V. A. · Proc. Natl. Acad. Sci. U.S.A. · 2005 · 102 · 432810.1073/pnas.0500929102 ↗
6. Kedersha N. L. · J. Cell Biol. · 1990 · 110 · 89510.1083/jcb.110.4.895 ↗
7. Scheffer G. L. · Nat. Med. · 1995 · 1 · 57810.1038/nm0695-578 ↗
8. Kowalski M. P. · Science · 2007 · 317 · 13010.1126/science.1142311 ↗
9. Kedersha N. L. · J. Cell Biol. · 1991 · 112 · 22510.1083/jcb.112.2.225 ↗
10. Mikyas Y. · J. Mol. Biol. · 2004 · 344 · 9110.1016/j.jmb.2004.09.021 ↗
11. Kickhoefer V. A. · J. Cell Biol. · 1999 · 146 · 91710.1083/jcb.146.5.917 ↗
12. Anderson D. H. · PLoS Biol. · 2007 · 5 · e31810.1371/journal.pbio.0050318 ↗
13. Stephen A. G. · J. Biol. Chem. · 2001 · 276 · 2321710.1074/jbc.C100226200 ↗
14. Poderycki M. J. · Biochemistry · 2006 · 45 · 1218410.1021/bi0610552 ↗
15. Goldsmith L. E. · Biochemistry · 2007 · 46 · 286510.1021/bi0606243 ↗
16. 10.1021/nn800638x10.1021/nn800638x ↗
17. Wiethoff C. M. · J. Virol. · 2005 · 79 · 199210.1128/JVI.79.4.1992-2000.2005 ↗
18. Hossann M. · Biochim. Biophys. Acta · 2007 · 249110.1016/j.bbamem.2007.05.021 ↗
19. Baum P. · J. Drug Targeting · 2007 · 15 · 39910.1080/10611860701453034 ↗
20. Wasungu L. · J. Controlled Release · 2006 · 116 · 25510.1016/j.jconrel.2006.06.024 ↗
21. Simberg D. · J. Biol. Chem. · 2003 · 278 · 3985810.1074/jbc.M302232200 ↗
22. Gharwan H. · Gene Ther. · 2007 · 10 · 81010.1038/sj.gt.3301954 ↗
23. Hong S. S. · J. Virol. · 2003 · 77 · 1036610.1128/JVI.77.19.10366-10375.2003 ↗
24. Rahman A. · Mol. Ther. · 2001 · 3 · 76810.1006/mthe.2001.0316 ↗
25. Kaddis C. S. · J. Am. Soc. Mass Spectrom. · 2007 · 18 · 120610.1016/j.jasms.2007.02.015 ↗
26. Blumenthal R. · Biochemistry · 1986 · 25 · 223110.1021/bi00356a057 ↗
27. Haidar M. A. · Philos. Trans. R. Soc. London, Ser. B · 1976 · 276 · 16510.1098/rstb.1976.0107 ↗
28. Goodman R. M. · Philos. Trans. R. Soc. London, Ser. B · 1976 · 276 · 17310.1098/rstb.1976.0108 ↗
29. Hed J. · J. Immunol. Methods · 1987 · 101 · 11910.1016/0022-1759(87)90224-9 ↗
30. Barbiei L. · Biochim. Biophys. Acta · 1993 · 1154 · 23710.1016/0304-4157(93)90002-6 ↗
31. Weyergang A. · J. Controlled Release · 2006 · 111 · 16510.1016/j.jconrel.2005.12.002 ↗
32. Yip W. L. · Mol. Pharmacol. · 2007 · 4 · 24110.1021/mp060105u ↗
33. Walters R. · Gene Ther. · 1999 · 6 · 184510.1038/sj.gt.3301020 ↗
34. Lee J. H. · Hum. Gene Ther. · 1999 · 10 · 60310.1089/10430349950018670 ↗
35. Toyoda K. · Gene Ther. · 2007 · 10 · 603
36. Seiler M. P. · Mol. Ther. · 2007 · 15 · 38610.1038/sj.mt.6300029 ↗